285 related articles for article (PubMed ID: 28741453)
21. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
Marotta V; Ramundo V; Camera L; Del Prete M; Fonti R; Esposito R; Palmieri G; Salvatore M; Vitale M; Colao A; Faggiano A
Clin Endocrinol (Oxf); 2013 May; 78(5):760-7. PubMed ID: 23009688
[TBL] [Abstract][Full Text] [Related]
22. Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.
Bae S; D'Cunha R; Shao J; An G
Eur J Pharm Sci; 2018 May; 117():27-34. PubMed ID: 29425861
[TBL] [Abstract][Full Text] [Related]
23. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
24. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
25. Hypothyroidism in adults. Levothyroxine if warranted by clinical and laboratory findings, not for simple TSH elevation.
Prescrire Int; 2015 Oct; 24(164):241-4, 246. PubMed ID: 26594730
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
27. Comparison of pathophysiology in subclinical hyperthyroidism with different etiologies.
Deguchi-Horiuchi H; Ito M; Takahashi S; Kousaka K; Hisakado M; Fukata S; Kudo T; Nishihara E; Nishikawa M; Miyauchi A; Akamizu T
Endocr J; 2024 Apr; 71(4):373-381. PubMed ID: 38296546
[TBL] [Abstract][Full Text] [Related]
28. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
[TBL] [Abstract][Full Text] [Related]
29. Timing of multikinase inhibitor initiation in differentiated thyroid cancer.
Brose MS; Smit J; Lin CC; Pitoia F; Fellous M; DeSanctis Y; Schlumberger M; Tori M; Sugitani I
Endocr Relat Cancer; 2017 May; 24(5):237-242. PubMed ID: 28270435
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
31. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
Kim A; McCully C; Cruz R; Cole DE; Fox E; Balis FM; Widemann BC
Invest New Drugs; 2012 Apr; 30(2):524-8. PubMed ID: 21072558
[TBL] [Abstract][Full Text] [Related]
32. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
33. Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients.
Ain KB; Pucino F; Shiver TM; Banks SM
Thyroid; 1993; 3(2):81-5. PubMed ID: 8369656
[TBL] [Abstract][Full Text] [Related]
34. Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.
Molenaar-Kuijsten L; Braal CL; Groenland SL; de Vries N; Rosing H; Beijnen JH; Koolen SLW; Vulink AJE; van Dongen MGJ; Mathijssen RHJ; Huitema ADR; Steeghs N;
Clin Pharmacol Ther; 2022 Feb; 111(2):477-484. PubMed ID: 34674222
[TBL] [Abstract][Full Text] [Related]
35. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
[TBL] [Abstract][Full Text] [Related]
36. Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Toffalorio F; Spitaleri G; Catania C; Dal Zotto L; Noberasco C; Delmonte A; Santarpia M; Vecchio F; Brunelli V; Rampinelli C; Barberis M; Fumagalli C; Zucchetti M; Zangarini M; Diena T; Danesi R; de Braud F; De Pas T
Oncologist; 2014 Apr; 19(4):344-5. PubMed ID: 24674875
[TBL] [Abstract][Full Text] [Related]
37. Safety of orally administered, USP-compliant levothyroxine sodium tablets in dogs.
Hare JE; Morrow CMK; Caldwell J; Lloyd WE
J Vet Pharmacol Ther; 2018 Apr; 41(2):254-265. PubMed ID: 29139142
[TBL] [Abstract][Full Text] [Related]
38. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
Kim A; Dombi E; Tepas K; Fox E; Martin S; Wolters P; Balis FM; Jayaprakash N; Turkbey B; Muradyan N; Choyke PL; Reddy A; Korf B; Widemann BC
Pediatr Blood Cancer; 2013 Mar; 60(3):396-401. PubMed ID: 22961690
[TBL] [Abstract][Full Text] [Related]
40. Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Kim GM; Kim MD; Kim do Y; Kim SH; Won JY; Park SI; Lee do Y; Shin W; Shin M
J Vasc Interv Radiol; 2016 Jul; 27(7):1086-92. PubMed ID: 27179404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
